Clinical trials recruiting in Suining, China

Phase breakdown

Conditions recruiting in Suining, China

Recruiting trials in Suining, China

• A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis
  NCT07724366 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
  NCT07667803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
  NCT05774951 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
  NCT06952803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
  NCT06430801 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
  NCT07761117 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma
  NCT06471257 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
  NCT07673029 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC
  NCT07748325 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
  NCT07190209 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
  NCT06079983 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Phase II Study of RC1416 Injection in COPD
  NCT07402551 · Phase: Phase 2 · Ages: 40 Years to 85 Years · Sex: All (male and female)
• Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
  NCT00271180 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female)
• Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
  NCT06993506 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
  NCT06136624 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
  NCT07047365 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection
  NCT06829784 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management
  NCT06909773 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years and older · Sex: All (male and female)
• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
  NCT07028853 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
  NCT06862206 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female)
• eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
  NCT07177339 · Phase: Phase 3 · Ages: 40 Years to 75 Years · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Suining, China?

21 recruiting trials have at least one study site in Suining, China.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.